New Pathway Found That Cripples Brain Immune Cells After Brain Bleed

Subarachnoid hemorrhage (SAH) — most commonly caused by a ruptured brain aneurysm — triggers a cascade of neuroinflammation that largely determines whether patients recover or sustain lasting neurological damage. Microglia, the brain's resident immune cells, are supposed to protect neurons by phagocytosing toxic blood byproducts and cellular debris, but after SAH their function becomes profoundly impaired. Understanding why this impairment occurs and how to reverse it is one of the central unresolved problems in SAH biology. This study, from Nanjing University's Drum Tower Hospital neurosurgery group, used a multi-omics strategy — combining whole-transcriptome RNA sequencing with untargeted LC-MS metabolomics on SAH-modeled microglia — to identify 5-lipoxygenase (5-LOX) as the pivotal molecular switch governing microglial dysfunction after hemorrhage.

The researchers established both in vivo (endovascular puncture in male C57BL/6 mice, n=6 per group) and in vitro (25 µM hemoglobin-treated primary microglia, BV2, and human HMC3 cells) SAH models. In mice, neurological function measured by open-field test and rotarod latency, as well as Nissl-staining neuronal counts, were significantly worse on day 1 post-SAH and partially recovered over subsequent days. Microglial phagocytic capacity tracked this same time course, declining sharply at 24 hours. Integrated transcriptomic and metabolomic KEGG pathway analysis converged on the arachidonic acid metabolism pathway and specifically on the 5-LOX node as the top differentially regulated feature. Differential expression analysis (DESeq2, |log2FC| ≥1, p<0.05) and OPLS-DA metabolomics (VIP>1, p<0.05) both flagged 5-LOX-related lipid mediators as the most changed signals.

The mechanistic core of the paper is a linear signaling cascade: SAH-induced extracellular ATP activates the purinergic receptor P2X7, flooding microglia with Ca²⁺. Elevated intracellular Ca²⁺ activates CaMKII, which phosphorylates 5-LOX and drives its nuclear translocation. In the nucleus, 5-LOX preferentially catalyzes LTB4 synthesis; outside the nucleus it generates the pro-resolving lipid LXA4. ELISA quantification confirmed a sharply elevated LTB4/LXA4 ratio in SAH-treated microglia. Elevated LTB4 further increases cytoplasmic Ca²⁺ while LXA4 suppresses it — creating a feed-forward loop that sustains calcium dysregulation. Excess intracellular Ca²⁺ impairs lysosomal acidification (measured with LysoTracker and LAMP1/cathepsin D immunofluorescence), collapsing the microglia's ability to degrade phagocytosed material and complete phagocytosis (assessed by pHrodo E. coli BioParticles flow cytometry).

Two intervention strategies broke this cascade at different points. First, exogenous resolvin D1 (RvD1, 25 nM) — a lipid mediator that inhibits 5-LOX nuclear translocation — reduced nuclear 5-LOX, lowered the LTB4/LXA4 ratio, dampened intracellular Ca²⁺, restored lysosomal acidification, and improved the phagocytic index in hemoglobin-treated microglia. Direct supplementation with LXA4 (100 nM) achieved a similar rebalancing of the LTB4/LXA4 ratio and downstream benefits. Second, upstream blockade with the P2X7 antagonist JNJ (100 nM) or P2X7 siRNA reduced CaMKII activation, suppressed 5-LOX nuclear translocation, and rescued lysosomal and phagocytic function in vitro. Critically, in vivo P2X7 siRNA treatment of SAH mice also improved rotarod scores, open-field locomotion, and Nissl-stained neuron preservation, while reducing brain IL-1β, IL-6, and TNF-α levels by ELISA, demonstrating that the pathway is therapeutically tractable in a living animal model.

The study provides unusually mechanistic clarity on how a known receptor (P2X7) connects to a known enzyme (5-LOX) through a lipid-mediator imbalance to produce organelle-level dysfunction in brain immune cells following acute hemorrhage. For clinicians, the P2X7–CaMKII–5-LOX axis represents a potentially druggable target; P2X7 antagonists and 5-LOX inhibitors such as zileuton already exist in pharmacology. For the longevity and brain-health audience, the findings reinforce that microglial lysosomal health — its capacity for autophagy and phagocytosis — is not a static property but is dynamically regulated by lipid signaling and calcium homeostasis, themes directly relevant to age-related neurodegeneration.